Company Overview
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Why Investors Should Care
Net profit has compounded at 14.0% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.21.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
- 5-Year Trend Long-term compounding — profit CAGR 14.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Compounded Profit Growth
| 5 Years: | 14.04% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +253.73% |
| 6 Months: | +88.84% |
| 3 Months: | +18.20% |
| 1 Month: | +8.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.19 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 14.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 28.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZNTL Zentalis Pharmaceuticals, Inc. | 4.74 | -2.72 | $337.42M | 0.00% | -57.45% | -51.93% | - | 14.04% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 37.83M | 36.06M | 33.73M | 37.39M | 37.85M |
| Operating Income | - | -37.83M | -36.06M | -33.73M | -37.39M | -37.85M |
| EBITDA | - | -37.56M | -35.90M | -33.57M | -37.24M | -37.70M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -48.28M | -26.87M | -26.69M | -34.77M | -35.23M |
| Tax Provision | - | 0 | 0 | 0 | 442.00K | 120.00K |
| Net Income | - | -48.28M | -26.87M | -26.69M | -35.22M | -35.35M |
| Diluted EPS | - | -0.67 | -0.37 | -0.37 | - | -0.50 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 67.42M | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 227.29M | 253.94M | 254.88M | 145.01M |
| Operating Income | - | -227.29M | -253.94M | -187.46M | -145.01M |
| EBITDA | - | -225.86M | -252.55M | -186.17M | -144.27M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -221.30M | -276.89M | -165.69M | -136.62M |
| Tax Provision | - | -469.00K | -601.00K | 177.00K | 442.00K |
| Net Income | - | -236.81M | -292.19M | -165.84M | -137.06M |
| Diluted EPS | - | -4.48 | -4.47 | -2.33 | -1.91 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 539.31M | 551.69M | 430.34M | 288.97M |
| Current Assets | - | 451.93M | 496.72M | 386.07M | 253.19M |
| Cash & Equivalents | - | 43.07M | 28.04M | 33.90M | 35.99M |
| Inventory | - | - | - | - | - |
| Receivables | 4.00K | - | - | - | - |
| Total Liabilities | - | 105.29M | 114.30M | 93.15M | 72.76M |
| Current Liabilities | - | 56.65M | 69.37M | 52.73M | 36.56M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 45.17M | 43.15M | 39.58M | 35.70M |
| Total Equity | - | 433.80M | 437.28M | 337.19M | 216.20M |
| Shares Outstanding | - | 59.28M | 70.77M | 71.28M | 69.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -163.75M | -207.82M | -170.86M | -125.25M |
| Investing Cash Flow | - | -114.18M | -44.46M | 176.56M | 131.62M |
| Financing Cash Flow | - | 261.04M | 237.30M | 108.00K | -4.28M |
| Capital Expenditure | -6.11M | -2.55M | -583.00K | -221.00K | - |
| Free Cash Flow | - | -166.30M | -208.41M | -171.08M | -125.25M |
| Net Change in Cash | - | -16.89M | -14.98M | 5.81M | 2.09M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | -278.0% | - |
| Net Margin % | - | - | - | -246.0% | - |
| ROE % | - | -54.6% | -66.8% | -49.2% | -63.4% |
| ROCE % | - | -47.1% | -52.6% | -49.6% | -57.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | 5AM Venture Management, LLC | 5.55% | 3.95M | $18.71M |
| 2 | Squadron Capital Management LLC | 5.10% | 3.63M | $17.21M |
| 3 | Two Sigma Investments, LP | 4.15% | 2.96M | $14.01M |
| 4 | Acadian Asset Management. LLC | 4.00% | 2.85M | $13.50M |
| 5 | Vanguard Capital Management LLC | 3.25% | 2.31M | $10.95M |
| 6 | Renaissance Technologies, LLC | 2.72% | 1.94M | $9.19M |
| 7 | Citadel Advisors Llc | 2.43% | 1.73M | $8.21M |
| 8 | Shaw D.E. & Co., Inc. | 2.08% | 1.48M | $7.03M |
| 9 | Opaleye Management Inc. | 1.98% | 1.41M | $6.70M |
| 10 | Decheng Capital LLC | 1.86% | 1.32M | $6.27M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZNTL
ZNTL — Frequently Asked Questions
What is the current share price of Zentalis Pharmaceuticals, Inc. (ZNTL)?
As of 2026-08-02 19:16 PDT, Zentalis Pharmaceuticals, Inc. (ZNTL) trades at $4.74 on NasdaqGM. Its 52-week range is $1.28 to $6.61.
What is the market capitalisation of ZNTL?
Zentalis Pharmaceuticals, Inc. (ZNTL) has a market capitalisation of $337.42M on NasdaqGM.
What is the P/E ratio of ZNTL?
ZNTL trades at a trailing price-to-earnings (P/E) ratio of -2.72. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 1.85.
What is the return on equity (ROE) of ZNTL?
ZNTL has a return on equity (ROE) of -51.93%. Its return on capital employed (ROCE) is -57.45%.
Is ZNTL a good stock to buy?
This page provides a data-driven analysis of Zentalis Pharmaceuticals, Inc. (ZNTL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.